Skip to main navigationSkip to main contentSkip to footer HealthSpring logo HealthSpring logo
Search
Español
  • Availity® Essentials
  • Availity® Essentials
  • Home Providers Medical Policies

    Medical policies

    Medical policies are based on research that provides evidence of scientific merit for a particular medical technology. They are also based on data from the peer-reviewed scientific literature, from criteria developed by specialty societies, from guidelines adopted by other health care organizations and from government agencies, such as the Centers for Medicare & Medicaid Services and the U.S. Food and Drug Administration. Medical policies are used as guidelines for coverage determinations in health care benefit programs, unless otherwise indicated.

    These medical policies apply only to members who have health insurance through HealthSpring.

    In the event of conflict between a medical policy and any plan document under which a member is entitled to covered services, the plan document will govern. Plan documents include, but are not limited to, Evidence of Coverage, benefit booklets, summary plan descriptions and other coverage documents.

    Medical technology is constantly evolving, and these medical policies are subject to change without notice, except as required by law. Additional medical policies may be developed from time to time, and some may be withdrawn from use. The medical policies generally apply to all benefit plans, although some local variations may exist. Members should call the number on their ID card for specific coverage information.

    Restrictions and limitations

    Medical policies serve as one of the sets of guidelines for coverage decisions. Benefit plans vary in coverage, and some plans may not provide coverage for certain services discussed in the medical policies.

    Coverage decisions are subject to all terms and conditions of the applicable benefit plan, including specific exclusions and limitations, and to applicable state and/or federal law. Medical policy does not constitute plan authorization, nor is it an explanation of benefits.

    The medical policies do not constitute medical advice or medical care. They do not guarantee any results or outcomes. Treating health care providers are solely responsible for diagnosis, treatment and medical advice. Members should discuss the information in the medical policies with their treating health care providers. HealthSpring is not a provider of health care and does not render medical advice.

    Medical policies can be highly technical and complex and are provided here for informational purposes.

    HealthSpring is under no obligation to update this site. Therefore, the medical policies displayed may be out of date. Contact your provider representative if you have any questions. Medical policies are interpreted and applied at the sole discretion of HealthSpring.

    Medical policies are interpreted and applied at the sole discretion of HealthSpring. Refer to our provider manual for more details. 

    Following are HealthSpring medical policies:

    Administrative

    Title
    Policy number
    Effective date

    Inside the U.S. Food and Drug Administration

    ADM1001.028
    May 7, 2026

    Durable medical equipment

    Title
    Policy number
    Effective date

    Durable Medical Equipment Reference List

    DME101.000
    July 21, 2026

    Hospital Beds and Related Equipment

    DME101.001
    May 7, 2026

    Wheelchairs and Accessories

    DME101.010
    May 7, 2026

    Brain Computer Interface Rehabilitation Devices

    DME101.054
    July 21, 2026
    Powered Exoskeletons
    DME103.008
    Aug. 18, 2026

    Myoelectric Prosthetic and Orthotic Components for Upper Limb

    DME104.001
    May 7, 2026

    Speech Generating Devices

    DME104.009
    July 21, 2026

    Medicine

    Other

    Title
    Policy number
    Effective date

    Ranibizumab Injections, Implants and Biosimilars

    OTH903.041
    July 21, 2026

    Avacincaptad pegol

    OTH903.045
    May 7, 2026

    Prescription drugs

    Title
    Policy number
    Effective date

    Natalizumab and Associated Biosimilar(s)

    RX501.059
    May 7, 2026

    Eculizumab and Associated Biosimilar(s)

    RX501.066
    May 7, 2026
    Enzyme-Replacement Therapies for Lysosomal Storage Disorder (Excluding Gaucher and Pompe Disease)
    RX501.067
    July 21, 2026

    Ocrelizumab or Ocrelizumab and Hyaluronidase-ocsq

    RX501.085
    May 7, 2026

    Cerliponase alfa

    RX501.092
    May 7, 2026

    Esketamine Nasal Spray for Treatment-Resistant Depression

    RX501.105
    May 7, 2026

    Teprotumumab-trbw (Tepezza)

    RX501.110
    May 7, 2026
    Ustekinumab and Associated Biosimilars
    RX501.114
    July 21, 2026

    Tocilizumab and Associated Biosimilar(s)

    RX501.115
    May 7, 2026

    Inebilizumab-cdon

    RX501.127
    May 7, 2026

    Valoctocogene Roxaparvovec-rvox

    RX501.128
    Jan. 1, 2026

    Anifrolumab-fnia

    RX501.138
    May 7, 2026

    Denosumab and Biosimilars for Non-Oncologic Indications

    RX501.140
    July 21, 2026

    Efgartigimod alfa-fcab or Efgartigimod alfa and hyaluronidase-qvfc

    RX501.141
    July 21, 2026

    Inclisiran

    RX501.142
    May 7, 2026

    Long-Acting Injectable Antiretroviral Agents for Treatment of HIV

    RX501.145
    May 7, 2026

    Vutrisiran (Amvuttra®) and Patisiran (Onpattro®)

    RX501.146
    May 7, 2026

    Teplizumab-mzwv

    RX501.150
    May 7, 2026

    Ublituximab-xiiy

    RX501.153 
    May 7, 2026

    Wilate

    RX501.160
    May 7, 2026

    Gene Therapies for Treatment of Wounds in Dystrophic Epidermolysis Bullosa

    RX501.164
    May 7, 2026

    Mirikizumab-mrkz

    RX501.168
    May 7, 2026

    Crovalimab-akkz

    RX501.176
    May 7, 2026

    Donanemab-azbt

    RX501.177
    May 7, 2026

    Sutimlimab-jome

    RX501.180
    May 7, 2026

    Spesolimab-sbzo

    RX501.181
    May 7, 2026

    Pozelimab-bbfg

    RX501.182
    May 7, 2026
    Enzyme Replacement Therapy for Pompe Disease
    RX501.189
    July 21, 2026
    Enzyme Replacement Therapy for Gaucher Disease
    RX501.190
    July 21, 2026

    Burosumab (Crysvita)

    RX502.058
    May 7, 2026

    Oncology Medications

    RX502.061
    July 21, 2026

    Surgery

    Title
    Policy number
    Effective date

    Therapeutic Embolization and Vessel Occlusion to Treat Pelvic Conditions

    SUR701.015
    May 7, 2026

    Laser Interstitial Tumor Therapy

    SUR701.031
    May 7, 2026

    Kidney Transplant

    SUR703.007
    May 7, 2026

    Lung and Lobar Lung Transplant

    SUR703.010
    May 7, 2026

    Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia

    SUR703.027
    May 7, 2026

    Hematopoietic Cell Transplantation for Genetic Diseases and Acquired Anemias

    SUR703.033
    May 7, 2026

    Hematopoietic Cell Transplantation for Breast Cancer

    SUR703.038
    May 7, 2026

    Hematopoietic Cell Transplantation for Walderström Macroglobulinemia

    SUR703.050
    May 7, 2026

    Bioengineered Skin and Soft Tissue Substitutes and Amniotic Membrane Products

    SUR704.011
    Aug. 18, 2026
    Bioengineered Skin and Soft Tissue Substitutes
    SUR704.012
    Aug. 18, 2026

    Temporomandibular Joint Disorders

    SUR705.010
    May 7, 2026

    Unicondylar Interpositional Spacer as a Treatment of Unicompartmental Arthritis of the Knee

    SUR705.024
    May 7, 2026

    Orthognathic Surgery

    SUR705.030
    May 7, 2026

    Shoulder Resurfacing

    SUR705.032
    May 7, 2026

    Ablation of Peripheral Nerves to Treat Pain

    SUR705.040
    June 16, 2026

    Genicular Artery Embolization

    SUR705.048
    June 16, 2026

    Use of a Medial Knee Implantable Shock Absorber

    SUR705.051
    May 7, 2026

    Radiofrequency Volumetric Tissue Reduction for Nasal Obstruction

    SUR706.001
    May 7, 2026

    Varicose Vein Management

    SUR707.016
    May 7, 2026

    Liposuction for Lipedema and Lymphedema

    SUR708.003
    May 7, 2026

    Nerve Graft with Radical Prostatectomy

    SUR710.019
    May 7, 2026

    Radiofrequency Energy Therapy for Stress Urinary Incontinence

    SUR710.021
    May 7, 2026

    Lysis of Epidural Adhesions

    SUR712.024
    May 7, 2026

    Artificial Intervertebral Disc

    SUR712.028
    May 7, 2026

    Aqueous Shunts and Stents for Glaucoma

    SUR713.034
    May 7, 2026

    Gender Assignment Surgery and Gender Reassignment Surgery with Related Services

    SUR717.001
    May 7, 2026

    Therapy

    Title
    Policy number
    Effective date
    Baroflex Stimulation Devices
    THE801.034
    Aug. 18, 2026

    Manipulation under Anesthesia

    THE803.016
    May 7, 2026

    Current Procedural Terminology (CPT®) codes and descriptions are the property of the American Medical Association with all rights reserved.

    The five-character codes included in the medical policies are obtained from the Physician's Current Procedural Terminology (CPT), copyright 2025 by the American Medical Association. CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physicians. CPT is a registered trademark of the AMA.

    The responsibility for the content of the medical policies is with HealthSpring, and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in the medical policies. CPT is provided “as is” without warranty of any kind, either expressed or implied, including but not limited to the implied warranties of merchantability and fitness for a particular purpose.

    No fee schedules, basis unit values, relative value guides, conversion factors or scales are included in any part of CPT. Any use of CPT outside of the medical policies should refer to the most current Physician's Current Procedural Terminology, which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.